Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VYGR 
Voyager Therapeutics Inc (VYGR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VYGR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.67
1 Year Target Price $15.67
| 11 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.4% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 295.65M USD | Price to earnings Ratio - | 1Y Target Price 15.67 |
Price to earnings Ratio - | 1Y Target Price 15.67 | ||
Volume (30-day avg) 12 | Beta 0.95 | 52 Weeks Range 2.65 - 8.17 | Updated Date 10/17/2025 |
52 Weeks Range 2.65 - 8.17 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.86 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -253.49% | Operating Margin (TTM) -704.33% |
Management Effectiveness
Return on Assets (TTM) -20.3% | Return on Equity (TTM) -37.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 250439764 | Price to Sales(TTM) 6.94 |
Enterprise Value 250439764 | Price to Sales(TTM) 6.94 | ||
Enterprise Value to Revenue 5.88 | Enterprise Value to EBITDA 2.59 | Shares Outstanding 55468806 | Shares Floating 46006937 |
Shares Outstanding 55468806 | Shares Floating 46006937 | ||
Percent Insiders 16.18 | Percent Institutions 59.94 |
Upturn AI SWOT
Voyager Therapeutics Inc
Company Overview
History and Background
Voyager Therapeutics Inc. was founded in 2011 and focuses on developing gene therapies for neurological diseases. The company has evolved from early-stage research to clinical trials and partnerships with larger pharmaceutical companies.
Core Business Areas
- Gene Therapy Development: Voyager focuses on developing gene therapies for neurological diseases using its TRACER AAV capsid discovery platform.
- CNS Drug Discovery: The company utilizes its platform to create treatments for severe neurological diseases.
Leadership and Structure
Voyager Therapeutics is led by CEO Alfred Sandrock Jr., MD, PhD, and has a board of directors overseeing strategy and operations. The organizational structure is based around research and development, clinical trials, and partnerships.
Top Products and Market Share
Key Offerings
- VY-TAU01: An investigational gene therapy for Alzheimer's disease, targeting tau protein. Currently in preclinical stage. Competitors include Biogen (BIIB) and Eli Lilly (LLY) who are developing antibody treatments.
- TRACER AAV Capsid Discovery Platform: Voyager's proprietary platform for discovering and developing AAV capsids with improved tropism and delivery to the CNS. It is not a product but a technology, therefore, market share is irrelevant. Competitors include Selecta Biosciences (SELB), REGENXBIO (RGNX).
Market Dynamics
Industry Overview
The gene therapy market is experiencing rapid growth, driven by technological advances and increasing investment in neurological disease research. Regulatory pathways are becoming more defined, facilitating approvals.
Positioning
Voyager is positioned as a leader in gene therapy for neurological diseases with its TRACER platform offering a competitive advantage in capsid discovery and delivery.
Total Addressable Market (TAM)
The estimated TAM for neurological disease treatments is in the billions of dollars annually, with gene therapy representing a growing share. Voyager is aiming to capture a significant portion of this market through its innovative platform.
Upturn SWOT Analysis
Strengths
- Proprietary TRACER AAV capsid discovery platform
- Focus on neurological diseases
- Experienced leadership team
- Strategic partnerships with larger pharmaceutical companies
Weaknesses
- High research and development costs
- Reliance on clinical trial outcomes
- Limited revenue streams at the current time
- Cash burn
Opportunities
- Expanding the application of TRACER platform to other diseases
- Securing regulatory approvals for lead product candidates
- Forming new partnerships for development and commercialization
- Growing demand for innovative treatments for neurological disorders
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene therapy companies
- Patent disputes
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- SELB
- RGNX
Competitive Landscape
Voyager's advantage lies in its TRACER platform. However, Biogen and Eli Lilly hold larger market shares in neurological disease treatments due to their established products.
Growth Trajectory and Initiatives
Historical Growth: Voyager's growth has been driven by its pipeline advancement and partnerships. Significant milestones from R&D and clinical trials impact short-term growth trends.
Future Projections: Future growth is dependent on clinical trial outcomes for VY-TAU01 and other pipeline candidates. Analyst estimates vary based on perceived probabilities of success.
Recent Initiatives: Focus on expanding the TRACER platform, advancing VY-TAU01 into clinical trials, and securing collaborations with pharmaceutical companies.
Summary
Voyager Therapeutics is a promising gene therapy company focused on neurological diseases. Its TRACER platform offers a competitive advantage. The company is dependent on successful clinical trial outcomes and regulatory approvals. Cash burn and competition pose risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Voyager Therapeutics Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports
- Other gene therapy market research
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data is based on publicly available information and may be subject to change. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Voyager Therapeutics Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2015-11-11 | President, CEO & Director Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 172 | |
Full time employees 172 | |||
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.